• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种基于治疗前计算机断层扫描纹理的新的肿瘤异质性部位间表征可根据临床结果对卵巢癌进行分类。

A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome.

作者信息

Vargas Hebert Alberto, Veeraraghavan Harini, Micco Maura, Nougaret Stephanie, Lakhman Yulia, Meier Andreas A, Sosa Ramon, Soslow Robert A, Levine Douglas A, Weigelt Britta, Aghajanian Carol, Hricak Hedvig, Deasy Joseph, Snyder Alexandra, Sala Evis

机构信息

Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.

Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.

出版信息

Eur Radiol. 2017 Sep;27(9):3991-4001. doi: 10.1007/s00330-017-4779-y. Epub 2017 Mar 13.

DOI:10.1007/s00330-017-4779-y
PMID:28289945
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5545058/
Abstract

PURPOSE

To evaluate the associations between clinical outcomes and radiomics-derived inter-site spatial heterogeneity metrics across multiple metastatic lesions on CT in patients with high-grade serous ovarian cancer (HGSOC).

METHODS

IRB-approved retrospective study of 38 HGSOC patients. All sites of suspected HGSOC involvement on preoperative CT were manually segmented. Gray-level correlation matrix-based textures were computed from each tumour site, and grouped into five clusters using a Gaussian Mixture Model. Pairwise inter-site similarities were computed, generating an inter-site similarity matrix (ISM). Inter-site texture heterogeneity metrics were computed from the ISM and compared to clinical outcomes.

RESULTS

Of the 12 inter-site texture heterogeneity metrics evaluated, those capturing the differences in texture similarities across sites were associated with shorter overall survival (inter-site similarity entropy, similarity level cluster shade, and inter-site similarity level cluster prominence; p ≤ 0.05) and incomplete surgical resection (similarity level cluster shade, inter-site similarity level cluster prominence and inter-site cluster variance; p ≤ 0.05). Neither the total number of disease sites per patient nor the overall tumour volume per patient was associated with overall survival. Amplification of 19q12 involving cyclin E1 gene (CCNE1) predominantly occurred in patients with more heterogeneous inter-site textures.

CONCLUSION

Quantitative metrics non-invasively capturing spatial inter-site heterogeneity may predict outcomes in patients with HGSOC.

KEY POINTS

• Calculating inter-site texture-based heterogeneity metrics was feasible • Metrics capturing texture similarities across HGSOC sites were associated with overall survival • Heterogeneity metrics were also associated with incomplete surgical resection of HGSOC.

摘要

目的

评估高级别浆液性卵巢癌(HGSOC)患者CT上多个转移病灶的临床结局与放射组学衍生的部位间空间异质性指标之间的关联。

方法

一项经机构审查委员会批准的对38例HGSOC患者的回顾性研究。对术前CT上疑似HGSOC累及的所有部位进行手动分割。从每个肿瘤部位计算基于灰度相关矩阵的纹理,并使用高斯混合模型将其分为五个簇。计算部位间的成对相似性,生成部位间相似性矩阵(ISM)。从ISM计算部位间纹理异质性指标,并与临床结局进行比较。

结果

在评估的12个部位间纹理异质性指标中,那些反映部位间纹理相似性差异的指标与较短的总生存期(部位间相似性熵、相似性水平簇阴影和部位间相似性水平簇突出度;p≤0.05)和不完全手术切除(相似性水平簇阴影、部位间相似性水平簇突出度和部位间簇方差;p≤0.05)相关。每位患者的疾病部位总数和每位患者的总体肿瘤体积均与总生存期无关。涉及细胞周期蛋白E1基因(CCNE1)的19q12扩增主要发生在部位间纹理更异质的患者中。

结论

非侵入性捕获空间部位间异质性的定量指标可能预测HGSOC患者的结局。

关键点

• 计算基于部位间纹理的异质性指标是可行的 • 反映HGSOC部位间纹理相似性的指标与总生存期相关 • 异质性指标也与HGSOC的不完全手术切除相关

相似文献

1
A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome.一种基于治疗前计算机断层扫描纹理的新的肿瘤异质性部位间表征可根据临床结果对卵巢癌进行分类。
Eur Radiol. 2017 Sep;27(9):3991-4001. doi: 10.1007/s00330-017-4779-y. Epub 2017 Mar 13.
2
Association between CT-texture-derived tumor heterogeneity, outcomes, and BRCA mutation status in patients with high-grade serous ovarian cancer.高级别浆液性卵巢癌患者 CT 纹理特征肿瘤异质性与结局及 BRCA 基因突变状态的相关性研究。
Abdom Radiol (NY). 2019 Jun;44(6):2040-2047. doi: 10.1007/s00261-018-1840-5.
3
Integration of proteomics with CT-based qualitative and radiomic features in high-grade serous ovarian cancer patients: an exploratory analysis.蛋白质组学与 CT 定性和放射组学特征在高级别浆液性卵巢癌患者中的整合:一项探索性分析。
Eur Radiol. 2020 Aug;30(8):4306-4316. doi: 10.1007/s00330-020-06755-3. Epub 2020 Apr 6.
4
19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes.19q12 扩增和非扩增的高级别浆液性卵巢癌亚组,cyclin E1 过表达,其分子驱动因素和临床结局不同。
Gynecol Oncol. 2018 Nov;151(2):327-336. doi: 10.1016/j.ygyno.2018.08.039. Epub 2018 Sep 9.
5
High cyclin E1 protein, but not gene amplification, is prognostic for basal-like breast cancer.细胞周期蛋白E1蛋白水平高而非基因扩增,对基底样乳腺癌具有预后价值。
J Pathol Clin Res. 2022 Jul;8(4):355-370. doi: 10.1002/cjp2.269. Epub 2022 Apr 6.
6
Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes.19q12扩增(包括CCNE1和URI)在不同上皮性卵巢癌亚型中的特征分析
Exp Mol Pathol. 2015 Feb;98(1):47-54. doi: 10.1016/j.yexmp.2014.12.004. Epub 2014 Dec 16.
7
Survival time prediction in patients with high-grade serous ovarian cancer based on F-FDG PET/CT- derived inter-tumor heterogeneity metrics.基于 F-FDG PET/CT 衍生的肿瘤间异质性指标预测高级别浆液性卵巢癌患者的生存时间。
BMC Cancer. 2024 Mar 12;24(1):337. doi: 10.1186/s12885-024-12087-y.
8
Reduced RBX1 expression induces chromosome instability and promotes cellular transformation in high-grade serous ovarian cancer precursor cells.RBX1 表达降低可诱导高级别浆液性卵巢癌前体细胞中的染色体不稳定性并促进细胞转化。
Cancer Lett. 2021 Mar 1;500:194-207. doi: 10.1016/j.canlet.2020.11.051. Epub 2020 Dec 5.
9
CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes.CCNE1 和 BRD4 共扩增与高级别浆液性卵巢癌不良临床结局相关。
Gynecol Oncol. 2020 May;157(2):405-410. doi: 10.1016/j.ygyno.2020.01.038. Epub 2020 Feb 7.
10
Biomarker Assessment of HR Deficiency, Tumor Mutations, and Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy.卵巢癌中 HR 缺陷、肿瘤突变和拷贝数的生物标志物评估:与铂单药治疗后临床结局的关联。
Mol Cancer Res. 2018 Jul;16(7):1103-1111. doi: 10.1158/1541-7786.MCR-18-0034. Epub 2018 May 3.

引用本文的文献

1
A CT-based radiomics model for predicting progression-free survival in patients with epithelial ovarian cancer.一种基于CT的影像组学模型,用于预测上皮性卵巢癌患者的无进展生存期。
BMC Cancer. 2025 May 20;25(1):899. doi: 10.1186/s12885-025-14265-y.
2
Radiomics and radiogenomics: extracting more information from medical images for the diagnosis and prognostic prediction of ovarian cancer.放射组学和放射基因组学:从医学影像中提取更多信息用于卵巢癌的诊断和预后预测。
Mil Med Res. 2024 Dec 14;11(1):77. doi: 10.1186/s40779-024-00580-1.
3
From Images to Genes: Radiogenomics Based on Artificial Intelligence to Achieve Non-Invasive Precision Medicine in Cancer Patients.

本文引用的文献

1
Regional and temporal heterogeneity of epithelial ovarian cancer tumor biopsies: implications for therapeutic strategies.上皮性卵巢癌肿瘤活检的区域和时间异质性:对治疗策略的影响。
Oncotarget. 2016 Jul 9;12(24):2404-2417. doi: 10.18632/oncotarget.10505. eCollection 2021 Nov 23.
2
Genomic Characterization of High-Grade Serous Ovarian Cancer: Dissecting Its Molecular Heterogeneity as a Road Towards Effective Therapeutic Strategies.高级别浆液性卵巢癌的基因组特征:剖析其分子异质性以寻求有效的治疗策略。
Curr Oncol Rep. 2016 Jul;18(7):44. doi: 10.1007/s11912-016-0526-9.
3
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.
从图像到基因:基于人工智能的放射基因组学助力癌症患者实现无创精准医疗
Adv Sci (Weinh). 2025 Jan;12(2):e2408069. doi: 10.1002/advs.202408069. Epub 2024 Nov 13.
4
F-Fluoro-2-Deoxyglucose Positron Emission Tomography/Computed Tomography Measures of Spatial Heterogeneity for Predicting Platinum Resistance of High-Grade Serous Ovarian Cancer.氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描测量空间异质性预测高级别浆液性卵巢癌铂类耐药。
Cancer Med. 2024 Oct;13(20):e70287. doi: 10.1002/cam4.70287.
5
Advances in ovarian cancer radiomics: a bibliometric analysis from 2010 to 2024.卵巢癌影像组学的进展:2010年至2024年的文献计量分析
Front Oncol. 2024 Oct 1;14:1456932. doi: 10.3389/fonc.2024.1456932. eCollection 2024.
6
Metastatic Lung Adenocarcinomas: Development and Evaluation of Radiomic-Based Methods to Measure Baseline Intra-Patient Inter-Tumor Lesion Heterogeneity.转移性肺腺癌:基于影像组学的方法用于测量患者内肿瘤间病变异质性的开发与评估
J Imaging Inform Med. 2025 Feb;38(1):148-164. doi: 10.1007/s10278-024-01163-1. Epub 2024 Jul 17.
7
Radiomic-Based Approaches in the Multi-metastatic Setting: A Quantitative Review.多转移灶情况下基于影像组学的方法:定量综述
medRxiv. 2024 Jul 5:2024.07.04.24309964. doi: 10.1101/2024.07.04.24309964.
8
Enhancing Immunotherapy Response Prediction in Metastatic Lung Adenocarcinoma: Leveraging Shallow and Deep Learning with CT-Based Radiomics across Single and Multiple Tumor Sites.增强转移性肺腺癌免疫治疗反应预测:跨单个和多个肿瘤部位利用基于CT的放射组学的浅层和深度学习
Cancers (Basel). 2024 Jul 8;16(13):2491. doi: 10.3390/cancers16132491.
9
Radiomics analysis of ultrasound images to discriminate between benign and malignant adnexal masses with solid morphology on ultrasound.超声图像的放射组学分析用于鉴别超声检查中具有实性形态的附件区良恶性肿块。
Ultrasound Obstet Gynecol. 2025 Mar;65(3):353-363. doi: 10.1002/uog.27680. Epub 2025 Feb 2.
10
Lymphadenectomy in clinically early epithelial ovarian cancer and survival analysis (LILAC): a Gynecologic Oncology Research Investigators Collaboration (GORILLA-3002) retrospective study.临床早期上皮性卵巢癌的淋巴结切除术和生存分析(LILAC):妇科肿瘤学研究人员协作组(GORILLA-3002)回顾性研究。
J Gynecol Oncol. 2024 Jul;35(4):e75. doi: 10.3802/jgo.2024.35.e75. Epub 2024 Mar 12.
转移性黑色素瘤中抗PD-1治疗反应的基因组和转录组特征
Cell. 2016 Mar 24;165(1):35-44. doi: 10.1016/j.cell.2016.02.065. Epub 2016 Mar 17.
4
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.阿替利珠单抗用于接受铂类化疗后病情进展的局部晚期和转移性尿路上皮癌患者:一项单臂、多中心、2期试验。
Lancet. 2016 May 7;387(10031):1909-20. doi: 10.1016/S0140-6736(16)00561-4. Epub 2016 Mar 4.
5
Whole-genome characterization of chemoresistant ovarian cancer.耐药性卵巢癌的全基因组特征分析。
Nature. 2015 May 28;521(7553):489-94. doi: 10.1038/nature14410.
6
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.癌症免疫学。突变图谱决定非小细胞肺癌对程序性死亡受体1(PD-1)阻断治疗的敏感性。
Science. 2015 Apr 3;348(6230):124-8. doi: 10.1126/science.aaa1348. Epub 2015 Mar 12.
7
Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis.高级别浆液性卵巢癌的时空异质性:系统发育分析
PLoS Med. 2015 Feb 24;12(2):e1001789. doi: 10.1371/journal.pmed.1001789. eCollection 2015 Feb.
8
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.PTEN 失活导致对 PI(3)Kα 抑制剂的临床耐药。
Nature. 2015 Feb 12;518(7538):240-4. doi: 10.1038/nature13948. Epub 2014 Nov 17.
9
Association between morphologic CT imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: a hypothesis-generating study.高级别浆液性卵巢癌女性患者的CT形态学影像特征与预后相关基因特征之间的关联:一项假设生成研究。
Radiology. 2015 Mar;274(3):742-51. doi: 10.1148/radiol.14141477. Epub 2014 Nov 10.
10
Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach.采用定量放射组学方法通过无创成像解码肿瘤表型。
Nat Commun. 2014 Jun 3;5:4006. doi: 10.1038/ncomms5006.